These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26138905)

  • 1. Transient myeloproliferative disorder with partial trisomy 21.
    Takahashi T; Inoue A; Yoshimoto J; Kanamitsu K; Taki T; Imada M; Yamada M; Ninomiya S; Toki T; Terui K; Ito E; Shimada A
    Pediatr Blood Cancer; 2015 Nov; 62(11):2021-4. PubMed ID: 26138905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model.
    Ng AP; Hu Y; Metcalf D; Hyland CD; Ierino H; Phipson B; Wu D; Baldwin TM; Kauppi M; Kiu H; Di Rago L; Hilton DJ; Smyth GK; Alexander WS
    PLoS Genet; 2015 May; 11(5):e1005211. PubMed ID: 25973911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
    Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
    J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
    Alford KA; Reinhardt K; Garnett C; Norton A; Böhmer K; von Neuhoff C; Kolenova A; Marchi E; Klusmann JH; Roberts I; Hasle H; Reinhardt D; Vyas P;
    Blood; 2011 Aug; 118(8):2222-38. PubMed ID: 21715302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
    Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
    Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
    Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
    Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.
    Tsai MH; Hou JW; Yang CP; Yang PH; Chu SM; Hsu JF; Chiang MC; Huang HR
    Indian J Pediatr; 2011 Jul; 78(7):826-32. PubMed ID: 21287369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of GATA1 mutations and leukemogenesis in newborns with Down syndrome.
    Queiroz LB; Lima BD; Mazzeu JF; Camargo R; Córdoba MS; Q Magalhães I; Martins-de-Sá C; Ferrari I
    Genet Mol Res; 2013 Oct; 12(4):4630-8. PubMed ID: 24222239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A neonate with a unique non-Down syndrome transient proliferative megakaryoblastic disease.
    Bertrums EJ; Buijs A; van Grotel M; Dors N; de Rooij JD; de Haas V; Hopman S; Jongmans MC; Zwaan CM; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27667142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [GATA1 analysis in myeloproliferative disorders associated to trisomy 21].
    Fuster Soler JL; Norton A; Galera Miñarro A; Bermúdez Cortés M; Llinares Riestra ME; Ortuño Giner F
    An Pediatr (Barc); 2011 Jan; 74(1):31-7. PubMed ID: 20870473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital GATA1-mutated myeloproliferative disorder in trisomy 21 complicated by placental fetal thrombotic vasculopathy.
    Loh TJ; Lian DW; Iyer P; Lam JC; Kuick CH; Aung AC; Chang KT
    Hum Pathol; 2014 Nov; 45(11):2364-7. PubMed ID: 25248574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of 2 isogenic clones from a patient with Trisomy 21 and a GATA1 mutation.
    Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
    Stem Cell Res; 2023 Jun; 69():103098. PubMed ID: 37084616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities.
    Banno K; Omori S; Hirata K; Nawa N; Nakagawa N; Nishimura K; Ohtaka M; Nakanishi M; Sakuma T; Yamamoto T; Toki T; Ito E; Yamamoto T; Kokubu C; Takeda J; Taniguchi H; Arahori H; Wada K; Kitabatake Y; Ozono K
    Cell Rep; 2016 May; 15(6):1228-41. PubMed ID: 27134169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence against the current hypothesis of "gene dosage effects" of trisomy 21: ets-2, encoded on chromosome 21" is not overexpressed in hearts of patients with Down Syndrome.
    Greber-Platzer S; Schatzmann-Turhani D; Wollenek G; Lubec G
    Biochem Biophys Res Commun; 1999 Jan; 254(2):395-9. PubMed ID: 9918849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient myeloproliferative disorder with trisomy 12.
    Basu B; Gupta V
    Pediatr Hematol Oncol; 2010 Apr; 27(3):233-6. PubMed ID: 20367267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proto-oncogene ERG in megakaryoblastic leukemias.
    Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
    Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.